Why insider trading matters?

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

- Peter Lynch
Aimmune Therapeutics, Inc. (AIMT)
Sector: Healthcare; Industry: Biotechnology

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2020-03-12 BJERKHOLT ERIC Chief Financial Officer Buy 1,000 $15.10 $15,100 No
2020-03-09 BJERKHOLT ERIC Chief Financial Officer Buy 1,000 $18.97 $18,970 No
2019-09-18 BJERKHOLT ERIC Chief Financial Officer Buy 1,550 $22.57 $34,977 No
2018-06-13 BJERKHOLT ERIC Chief Financial Officer Buy 1,600 $30.41 $48,663 No
2018-02-26 BJERKHOLT ERIC Chief Financial Officer Buy 3,125 $32.00 $100,000 No
2017-05-12 BJERKHOLT ERIC Chief Financial Officer Buy 5,000 $19.84 $99,210 No

Insider Smart

ROYAL CARIBBEAN CRUISES (RCL) - Thompson Donald, Director of RCL feels safe and made a move. The only insiders bought RCL post crash.

Insider Smart

Altimmune, Inc. (ALT) - Venrock Healthcare Capital Partners III, L.P., 10%-owner of ALT bought 1.3M shares in late May then added another 1.5M shares in June with an averaged ~$8 per share. 10 days after the accumulation, ALT price jumped to $10.